首页> 外文期刊>Synapse >Functional Adaptation of Presynaptic Chemokine Receptors in EAE Mouse Central Nervous System
【24h】

Functional Adaptation of Presynaptic Chemokine Receptors in EAE Mouse Central Nervous System

机译:突触前趋化因子受体在EAE小鼠中枢神经系统中的功能适应。

获取原文
获取原文并翻译 | 示例
           

摘要

In cortical synaptosomes of Experimental Autoimmune Encephalomyelitis (EAE) mice at the early stage of disease (13 days post immunization, d.p.i.), the Regulated upon Activation Normal T cell Expressed and Secreted (RANTES, CCL5)-mediated control of [~3H]D-aspartate ([~3H]D-ASP) exocytosis elicited by a mild depolarizing stimulus (12 mM KCl) shifted from inhibition to facilitation. By using selective antagonists for the chemokine receptor (CCR) 1, 3, and 5 subtypes, we found that the pharmacological profile of the receptor(s) accounting for CCL5-mediated effect was unaltered when compared to control. Inasmuch, CCR protein expression was unaltered. This studies was not extended at 21 d.p.i. since, at this stage, CCL5 failed to affect [~3H]D-ASP exocytosis. At 13 d.p.i., the expression of CCR proteins was largely conserved when compared to control. In spinal cord synaptosomes of EAE mice at 21 d.p.i., when presynaptic defects became evident, the [~3H]D-ASP exocytosis elicited by 15 mM KCl was significantly increased when compared to control and it was significantly potentiated by 1 nM CCL5. The antagonist pharmacological profile and the western blot analysis of the CCR proteins unveiled that the receptor repertoire involved was unmodified. Differently from controls, however, the CCR1 antagonist BX513 efficiently inhibited on its own [~3H]D-ASP exocytosis suggesting that this receptor could have adopted an active conformation. Altogether, our observations favor the use of CCR antagonists to the cure of neurological symptoms in patients suffering from demyelinating syndrome.
机译:在疾病早期(免疫后13天,dpi)的实验性自身免疫性脑脊髓炎(EAE)小鼠的皮层突触体中,激活激活的正常T细胞表达和分泌(RANTES,CCL5)介导的[〜3H] D控制轻度去极化刺激(12 mM KCl)引起的天冬氨酸([〜3H] D-ASP)胞吐作用从抑制作用转变为促进作用。通过使用趋化因子受体(CCR)1,3和5亚型的选择性拮抗剂,我们发现,与对照相比,解释CCL5介导作用的受体的药理学特性没有改变。因此,CCR蛋白的表达未改变。这项研究没有在21 d.p.i进行。因为在此阶段,CCL5无法影响[〜3H] D-ASP的胞吐作用。与对照相比,在13 d.p.i.,CCR蛋白的表达在很大程度上得以保留。在21 d.p.i.的EAE小鼠的脊髓突触体中,当突触前​​缺陷变得明显时,与对照组相比,由15 mM KCl引起的[〜3H] D-ASP胞吐作用显着增加,并且被1 nM CCL5显着增强。 CCR蛋白的拮抗剂药理学特征和蛋白质印迹分析表明,涉及的受体库未修饰。但是,与对照不同,CCR1拮抗剂BX513可以有效抑制其自身的[〜3H] D-ASP胞吐作用,这表明该受体可能已经采用了活性构象。总而言之,我们的观察结果支持使用CCR拮抗剂来治愈脱髓鞘综合征患者的神经系统症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号